comparemela.com

Page 4 - Research Development Rd Expenses News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AbCellera Reports Full Year 2023 Business Results

Total revenue of $38 million, compared to $485 million in FY 2022Total cumulative partner-initiated program starts with downstreams of 87, with 12 new starts in the yearNet loss of $0.51 per share on a basic and diluted basis, compared to earnings of $0.56 (basic) and $0.50 (diluted) per share in 2022VANCOUVER, Brit.

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity

Global Healthcare CMO Market Insights and Forecast to 2027 - Increasing Demand for Active Pharmaceutical Ingredient (API) - ResearchAndMarkets com

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.